Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Filings indexed 912 across all filing types
Latest filing 2025-10-08 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.
Regulatory Filings
2025-10-08 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2025-10-08 English
Press Release
Regulatory Filings
2025-10-06 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated October 6, 2025, announcing that Wanbury Ltd. has successfully gone live with its SAP S/4HANA Private Cloud ERP system. It includes details about the implementation, strategic importance, and a quote from a company director. The document is addressed to stock exchanges and is intended for public information and record. There are no financial statements, quarterly or annual results, or detailed financial data. The document is a corporate announcement about an operational milestone rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. It is also not a management or board change announcement, nor a voting result or dividend notice. The content fits best as a general regulatory announcement informing the market about a significant operational update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-10-06 English
Closure of Trading Window
Regulatory Filings
2025-09-29 English
Trading Window
Regulatory Filings Classification · 95% confidence The document text is extremely short (691 characters) and contains only a digital signature block with no substantive content related to financial results, management changes, or any report. There is no mention of any report type, regulatory body, or financial data. The content resembles an officer certification or attestation rather than a full report or announcement. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2025-09-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.